Onconetix (NASDAQ:ONCO – Get Free Report)‘s stock had its “sell (e+)” rating reissued by equities research analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.
Onconetix Price Performance
ONCO opened at $3.53 on Friday. The business’s 50-day moving average is $3.16 and its two-hundred day moving average is $4.39. Onconetix has a 1 year low of $2.45 and a 1 year high of $339.15. The firm has a market capitalization of $5.47 million, a PE ratio of -0.02 and a beta of 3.39.
Onconetix (NASDAQ:ONCO – Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($4.05) earnings per share (EPS) for the quarter. Onconetix had a negative net margin of 3,327.03% and a negative return on equity of 192.74%. The company had revenue of $0.11 million during the quarter.
About Onconetix
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Read More
- Five stocks we like better than Onconetix
- 3 Dividend Kings To Consider
- Tractor Supply Stock Looks Like a Buy-and-Hold Winner
- How to Buy Gold Stock and Invest in Gold
- 3 Stocks Well Below 52-Week Highs Poised for a Q4 Rebound
- How to Plot Fibonacci Price Inflection Levels
- Big Banks Are Setting the Tone as Earnings Season Kicks Off
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
